Akorn Launches Ibuprofen Oral Suspension
November 29 2016 - 7:30AM
Akorn, Inc. (Nasdaq:AKRX), a leading specialty pharmaceutical
company, today announced that it has launched the prescription
version of Ibuprofen 100mg/5mL oral suspension in 118mL and 473mL
bottles as well as 5mL unit dose cups.
About Ibuprofen 100mg/5mL Oral
SuspensionIbuprofen Oral Suspension, USP is a
sucrose-sweetened, orange-colored, berry-flavored suspension
containing 100 mg of ibuprofen in 5 mL (20 mg/mL).
In Pediatric Patients, ibuprofen oral suspension
is indicated:
- For reduction of fever in patients aged 6 months up to 2 years
of age.
- For relief of mild to moderate pain in patients aged 6 months
up to 2 years of age.
- For relief of signs and symptoms of juvenile arthritis.
In Adults, ibuprofen oral suspension is
indicated:
- For treatment of primary dysmenorrhea.
- For relief of the signs and symptoms of rheumatoid arthritis
and osteoarthritis
According to IMS Health, sales of Ibuprofen
100mg/5mL oral suspension were approximately $18.6 million for the
twelve months ended September 30, 2016.
About AkornAkorn, Inc. is a
specialty generic pharmaceutical company engaged in the
development, manufacture and marketing of multisource and branded
pharmaceuticals. Akorn has manufacturing facilities located in
Decatur, Illinois; Somerset, New Jersey; Amityville, New York;
Hettlingen, Switzerland and Paonta Sahib, India that manufacture
ophthalmic, injectable and specialty sterile and non-sterile
pharmaceuticals. Additional information is available on Akorn’s
website at www.akorn.com.
Forward Looking StatementsThis
press release includes statements that may constitute "forward
looking statements", including statements regarding Akorn's goals
and strategy. When used in this document, the words “continue,”
“anticipate,” “plan,” “achieve,” “will,” “believe,” “estimate” and
“expect” and similar expressions are generally intended to identify
forward looking statements. These statements are made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Because such statements inherently involve
risks and uncertainties, actual future results may differ
materially from those expressed or implied by such forward looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to: the susceptibility of
our generic and off patent pharmaceutical products to competition,
substitution policies and reimbursement policies of the government;
the timing and success of product launches; difficulties or delays
in manufacturing; the availability and pricing of third party
sourced products and materials; successful compliance with FDA and
other governmental regulations; the continuing consolidation of our
customer base, which could adversely affect sales of our products;
our dependence on a small number of distributors, the loss of any
of which could have a material adverse effect; changes in the laws
and regulations and such other risks and uncertainties outlined in
Akorn's public filings with the SEC. Except as expressly required
by law, Akorn disclaims any intent or obligation to update these
forward looking statements.
Investors/Media:
Stephanie Carrington
ICR, Inc.
(646) 277-1282
Stephanie.carrington@icrinc.com
Akorn (NASDAQ:AKRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akorn (NASDAQ:AKRX)
Historical Stock Chart
From Apr 2023 to Apr 2024